The Efficacy of Silymarin and Vitamin E in Non-Alcoholic Fatty Liver Disease: A Clinical Trial

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 57
  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJDO-12-2_005

تاریخ نمایه سازی: 16 آبان 1402

Abstract:

Abstract Objective: Nowadays, lifestyle modification is the best treatment recommended to patients with the nonalcoholic fatty liver disease (NAFLD). The therapeutic effects of vitamin E and silybin on liver functions were documented. The present study was conducted to examine the effect of silymarin and vitamin E on patients with NAFLD. Materials and Methods: From September ۲۰۱۴ to March ۲۰۱۵, clinical trial was conducted on ۹۲ patients with NAFLD at ۲ Shahid Sadoughi university clinical research centers. Sampling was based on convenient method. There were no randomization or blinding in this study, but two types of treatments were compared. The patients were divided in two groups of daily intake of vitamin E (۴۰۰ IU) and Silymarin ۲۸۰ mg for four months. Alanine aminotransferase (ALT) and liver ultrasonography were done at baseline and after four months. Results: Eighty patients completed the course of treatment successfully .After ۴ months, both groups had experienced a significant reduction in their serum ALT levels. The mean change in the ALT level from the baseline was -۳۱.۶ U/L in the silymarin group vs. -۱۵.۱ U/L in the vitamin E group (P-value= ۰.۰۷). Treatment with silymarin was more effective than vitamin E (P-value< ۰.۰۰۰۱). The mean ALT level changed to normal was ۵۵.۰% (۲۲ of ۴۰ patients )in the silymarin group, while it was ۴۵.۰% (۱۸ of ۴۰ cases) in the vitamin E group (P-value= ۰.۰۴). Conclusion: The treatment of NAFLD with silymarin appears to be significantly effective in biochemical improvement whereas treatment with vitamin E improves ultrasonographic parameters.

Keywords:

Nonalcoholic fatty liver disease , Silymarin , Vitamin E , Clinical trial

Authors

Mohsen Akhondi-Meybodi

Associate Professor of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran

Mahmoud Baghbanian

Associate Professor of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran

Abolfazl Namazi

Internist of Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Science, Yazd, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, ...
  • Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, ...
  • Adams LA, Harmsen S, Sauver JL, Charatcharoenwitthaya P, Enders FB, ...
  • Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, ...
  • Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, ...
  • Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, ...
  • Loguercio C, Federico A, Trappoliere M, Tuccillo C, De Sio ...
  • Zhong S, Fan Y, Yan Q, Fan X, Wu B, ...
  • Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. ...
  • Saverymuttu, S. H., Joseph, A. E., & Maxwell, J. D. ...
  • Hajiani EP, Hashemi SJ. Comparison of therapeutic effects of silymarin ...
  • Solhi H, Ghahremani R, Kazemifar AM, Yazdi ZH. Silymarin in ...
  • Masoodi M, Rezadoost A, Panahian M, Vojdanian M. Effects of ...
  • Kheong CW, Mustapha NR, Mahadeva S. A randomized trial of ...
  • Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, ...
  • Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, ...
  • Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. ...
  • Musso G, Gambino R, Cassader M, Pagano G. A meta‐analysis ...
  • Cai J, Zhang XJ, Li H. Progress and challenges in ...
  • Feher J, Lengyel G. Silymarin in the prevention and treatment ...
  • Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: ...
  • Saller R, Brignoli R, Melzer J, Meier R. An updated ...
  • Federico A, Dallio M, Loguercio C. Silymarin/silybin and chronic liver ...
  • Perumpail BJ, Li AA, Iqbal U, Sallam S, Shah ND, ...
  • Hajagha MA, Ziaei A, Rafiei R.The efficacy of silymarin in ...
  • نمایش کامل مراجع